TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 11th, 2019 • Swedish Orphan Biovitrum AB (Publ) • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Purchaser”), and the stockholder listed on the signature page hereto (the “Stockholder”).
MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • May 25th, 2023 • Swedish Orphan Biovitrum AB (Publ) • Pharmaceutical preparations
THIS MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT (“Agreement”) is entered into as of March 3, 2023 (the “Effective Date”), by and between CTI BioPharma Corp., a Delaware corporation having its principal place of business located at 3101 Western Avenue, Suite 800, Seattle, WA 98121, and its affiliates and subsidiaries, and Swedish Orphan Biovitrum AB, having its place of business located at Tomtebodavägen 23A, SE-112 76 Stockholm, Sweden.
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 11th, 2019 • Swedish Orphan Biovitrum AB (Publ) • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Purchaser”), and each of the stockholders listed on the signature pages hereto (collectively, the “Stockholders”).
